Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL).
Phase 3 ELEVATE TN Study in CLL @SeattleCCA
